Cyclodextrin Inclusion Compounds for Low-Toxicity Viral Elimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Herpesvirales, Caudovirales, Mononegavirales, Nidovirales, Picornavirales, Tymovirales, and Retroviridae viruses, such as Herpes simplex and Herpes zoster, are ineffective in terminating the viral cycle and often cause adverse side effects due to high drug concentrations, with low bioavailability and limited efficacy.
Innovation Solution
Forming inclusion compounds with cyclodextrins and antiseptic agents, such as chlorhexidine, at low concentrations to modulate antiviral activity, effectively eliminating viruses by encapsulating the agents within the cyclodextrin cavity, thereby reducing toxicity and enhancing efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentrations of antiviral drugs are used to eliminate viruses, then viral elimination efficacy is improved, but toxicity and adverse side effects increase
Solution Approach 1:
Cyclodextrins serve as intermediary carriers that encapsulate antiviral agents, enabling controlled release and targeted delivery to viral particles. This mediator approach allows the active ingredient to achieve high local concentrations at the virus site while maintaining low systemic concentrations, thereby improving viral elimination efficacy without increasing overall toxicity and adverse side effects
Solution Approach 2:
The invention changes the concentration parameter distribution by using cyclodextrin inclusion compounds to deliver antiviral agents at low systemic concentrations while achieving high local concentrations at the virus site. This parameter transformation resolves the contradiction by decoupling systemic exposure from local efficacy, maintaining high viral elimination efficacy while reducing toxicity and adverse side effects
2Object-affected harmful factors
If low concentrations of antiviral agents are used to reduce toxicity, then safety is improved, but viral elimination efficacy decreases
Solution Approach 1:
The invention segments the antiviral agent delivery system into cyclodextrin carriers that can be selectively targeted to viral particles. This segmentation allows low concentrations of the antiviral agent to be distributed systemically without toxicity, while the cyclodextrin carriers concentrate the agent at the virus site, maintaining high viral elimination efficacy despite low overall concentrations
Solution Approach 2:
Cyclodextrins act as intermediary carriers that enable low concentrations of antiviral agents to achieve high local efficacy. The cyclodextrin-virus interaction ensures that even at low systemic concentrations, the antiviral agent is delivered in sufficient quantities to eliminate viruses, thus improving safety while maintaining viral elimination efficacy
3Quantity of substance
If conventional antiviral treatments are used to reduce viral load, then viral replication is inhibited, but the viral cycle is not terminated and the disease duration is prolonged
Solution Approach 1:
The cyclodextrin inclusion compounds are designed to preemptively bind to viral particles and deliver high concentrations of antiviral agents directly to the virus, preventing viral replication before it can establish persistent infection. This preliminary action at the virus-cel l interface terminates the viral cycle more effectively than conventional treatments that merely reduce viral load after replication has begun
Solution Approach 2:
The invention changes the temporal parameter of antiviral action by achieving rapid, high-concentration delivery to viral particles through cyclodextrin-mediated targeted release. This parameter change from slow, diffuse conventional delivery to rapid, concentrated targeted delivery terminates the viral cycle faster, reducing disease duration while effectively reducing viral load
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The inclusion compounds achieve high efficacy in eliminating viruses with low toxicity, demonstrated by 99.9% viral inactivation at safe concentrations, reducing the duration and severity of viral infections.
Implementation Method 1
cyclodextrins in association with an antiseptic active as the main agents, in a combined action that demonstrates high efficacy in eliminating the virus
Implementation Method 2
cyclodextrins (CDs) are widely used due to their high commercial availability, relatively low cost, low toxicity, established use in the formulation of inclusion compounds
Data Source
AI summary
The present invention relates to compositions comprising inclusion compounds with cyclodextrins and antiseptic actives for the elimination of viruses from the orders Herpesvirales, Caudovirales, Mononegavirales, Nidovirales, Picornavirales, Tymovirales, and from the family Retroviridae. More specifically, the present invention discloses a method for modulating the activity of an antiseptic agent for virucidal action through its association with beta-cyclodextrin and/or its derivatives, in a combined action that exhibits high effectiveness in eliminating viruses-not merely weakening them-while using low concentrations of antiseptic actives and exhibiting low toxicity